Stem Cell and Regenerative Therapy Market Monitoring Growth Opportunities 2024 – Aerospace Journal

The global stem cell and regenerative medicines market should grow from $21.8 billion in 2019 to reach $55.0 billion by 2024 at a compound annual growth rate (CAGR) of 20.4% for the period of 2019-2024.

Report Scope:

The scope of this report is broad and covers various type of product available in the stem cell and regenerative medicines market and potential application sectors across various industries. The current report offers a detailed analysis of the stem cell and regenerative medicines market.

Get Access to sample pages:https://www.trendsmarketresearch.com/report/sample/11723

The report highlights the current and future market potential of stem cell and regenerative medicines and provides a detailed analysis of the competitive environment, recent development, merger and acquisition, drivers, restraints, and technology background in the market. The report also covers market projections through 2024.

The report details market shares of stem cell and regenerative medicines based on products, application, and geography. Based on product the market is segmented into therapeutic products, cell banking, tools and reagents. The therapeutics products segments include cell therapy, tissue engineering and gene therapy. By application, the market is segmented into oncology, cardiovascular disorders, dermatology, orthopedic applications, central nervous system disorders, diabetes, others

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes:

28 data tables An overview of global markets for stem cell and regenerative medicines Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 Details of historic background and description of embryonic and adult stem cells Information on stem cell banking and stem cell research A look at the growing research & development activities in regenerative medicine Coverage of ethical issues in stem cell research & regulatory constraints on biopharmaceuticals Comprehensive company profiles of key players in the market, including Aldagen Inc., Caladrius Biosciences Inc., Daiichi Sankyo Co. Ltd., Gamida Cell Ltd. and Novartis AG

Summary

The global market for stem cell and regenerative medicines was valued at REDACTED billion in 2018. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED billion by 2024. Growth of the global market is attributed to the factors such as growingprevalence of cancer, technological advancement in product, growing adoption of novel therapeuticssuch as cell therapy, gene therapy in treatment of chronic diseases and increasing investment fromprivate players in cell-based therapies.

In the global market, North America held the highest market share in 2018. The Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period. The growing government funding for regenerative medicines in research institutes along with the growing number of clinical trials based on cell-based therapy and investment in R&D activities is expected to supplement the growth of the stem cell and regenerative market in Asia-Pacific region during the forecast period.

Reasons for Doing This Study

Global stem cell and regenerative medicines market comprises of various products for novel therapeutics that are adopted across various applications. New advancement and product launches have influenced the stem cell and regenerative medicines market and it is expected to grow in the near future. The biopharmaceutical companies are investing significantly in cell-based therapeutics. The government organizations are funding research and development activities related to stem cell research. These factors are impacting the stem cell and regenerative medicines market positively and augmenting the demand of stem cell and regenerative therapy among different application segments. The market is impacted through adoption of stem cell therapy. The key players in the market are investing in development of innovative products. The stem cell therapy market is likely to grow during the forecast period owing to growing investment from private companies, increasing in regulatory approval of stem cell-based therapeutics for treatment of chronic diseases and growth in commercial applications of regenerative medicine.

To Get Discount:https://www.trendsmarketresearch.com/report/discount/11723

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced many significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its current practical applications, evaluate the participating companies and look to its future.

The report provides the reader with a background on stem cell and regenerative therapy, analyzes the current factors influencing the market, provides decision-makers the tools that inform decisions about expansion and penetration in this market.

See the article here:
Stem Cell and Regenerative Therapy Market Monitoring Growth Opportunities 2024 - Aerospace Journal

Could an Imaging Test Predict How Well Youll Respond to a Stem Cell Transplant? – SurvivorNet

Dr. Jakub Svoboda Penn Medicine

If youve already gone through a round of treatment for diffuse large B-cell lymphoma and it didnt work, or your cancer came back after treatment, your doctor might start talking to you about having an autologous stem cell transplant. This therapy involves getting high doses of chemotherapy to get rid of your cancer cells, followed by an infusion of stem cells taken from your blood or bone marrow before treatment, to replenish your bodys supply of healthy blood cells.

Related: What is Autologous Stem Cell Transplant?

A stem cell transplant can be a pretty grueling treatment that involves getting very high doses of chemotherapy, spending three to four weeks in the hospital, and enduring side effects like nausea, vomiting, mouth pain, infections, bleeding, and lung inflammation. And after all of that, you still may not get the results you want.

If its going to cure the patient, I think its all worthwhile to go through, Dr. Jakub Svoboda, medical oncologist at Penn Medicine, tells SurvivorNet. If, on the other hand, a stem cell transplant isnt likely to result in a cure, it may not be a good choice for you.

One clue that can help your doctor decide whether a stem cell transplant is worth the risks involved is how well you responded to chemotherapy after your cancer relapsed. People with an aggressive lymphoma that didnt respond well to chemotherapy tend not to have a good outcome from a stem cell transplant.

Having a combination imaging test called a PET/CT scan before a stem cell transplant can help pinpoint your response to chemo, and let you avoid some potentially severe side effects if this treatment isnt likely to cure you. The PET/CT technology has allowed us to select the patients who will likely benefit from autologous STEM cell transplant, Dr. Svoboda says.

The PET/CT scan combines two common cancer imaging tests. PET stands for positron emission tomography. Before the test, you get an injection of a small amount of radioactive sugar, called fluorodeoxyglucose-18 (FGD-18). Because cancer cells use a lot more energy than healthy cells, they absorb the sugar in larger amounts. As the tracer collects in the cancer, it makes those areas light up and become visible, so your doctor can see them on the scan.

CT is short for computed tomography. It takes x-rays of your body from different angles, to create a cross-sectional view of your organs and tissues. The CT scan can reveal areas of your body that are enlarged from the cancer. It alone isnt sensitive enough to pick up metabolically active areas of cancer, which is why the two tests are combined.

A computer combines the PET and CT images to give your doctor a highly detailed, three-dimensional view of your cancer. Having both of these tests together can show your doctor not only whether your cancer is shrinking, but also if its still active.

When people still have some metabolic activity within shrinking areas of cancer, they actually dont do well with the transplant, Dr. Svoboda says.

Its very helpful for doctors to have the information from a PET/CT scan, Dr. Svoboda tells SurvivorNet. You can then offer that patient a different treatment or steer them toward some of the novel therapies.

One alternative to stem cell transplant is chimeric antigen receptor (CAR) T-cell therapy. Its a promising treatment for some people with aggressive non-Hodgkin lymphoma that hasnt responded to other treatments. CAR T-cell therapy involves genetically modifying your own immune cells so that they attack your cancer. CAR T-cell therapy or other treatments actually may have a better chance at working than transplanting in this setting, Dr. Svoboda says.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Jakub Svoboda is a medical oncologist at Penn Medicine, andassociate professor of medicine at the Hospital of the University of Pennsylvania. Read More

Dr. Jakub Svoboda Penn Medicine

Related: What is Autologous Stem Cell Transplant?

If its going to cure the patient, I think its all worthwhile to go through, Dr. Jakub Svoboda, medical oncologist at Penn Medicine, tells SurvivorNet. If, on the other hand, a stem cell transplant isnt likely to result in a cure, it may not be a good choice for you.

One clue that can help your doctor decide whether a stem cell transplant is worth the risks involved is how well you responded to chemotherapy after your cancer relapsed. People with an aggressive lymphoma that didnt respond well to chemotherapy tend not to have a good outcome from a stem cell transplant.

Having a combination imaging test called a PET/CT scan before a stem cell transplant can help pinpoint your response to chemo, and let you avoid some potentially severe side effects if this treatment isnt likely to cure you. The PET/CT technology has allowed us to select the patients who will likely benefit from autologous STEM cell transplant, Dr. Svoboda says.

The PET/CT scan combines two common cancer imaging tests. PET stands for positron emission tomography. Before the test, you get an injection of a small amount of radioactive sugar, called fluorodeoxyglucose-18 (FGD-18). Because cancer cells use a lot more energy than healthy cells, they absorb the sugar in larger amounts. As the tracer collects in the cancer, it makes those areas light up and become visible, so your doctor can see them on the scan.

CT is short for computed tomography. It takes x-rays of your body from different angles, to create a cross-sectional view of your organs and tissues. The CT scan can reveal areas of your body that are enlarged from the cancer. It alone isnt sensitive enough to pick up metabolically active areas of cancer, which is why the two tests are combined.

A computer combines the PET and CT images to give your doctor a highly detailed, three-dimensional view of your cancer. Having both of these tests together can show your doctor not only whether your cancer is shrinking, but also if its still active.

When people still have some metabolic activity within shrinking areas of cancer, they actually dont do well with the transplant, Dr. Svoboda says.

Its very helpful for doctors to have the information from a PET/CT scan, Dr. Svoboda tells SurvivorNet. You can then offer that patient a different treatment or steer them toward some of the novel therapies.

One alternative to stem cell transplant is chimeric antigen receptor (CAR) T-cell therapy. Its a promising treatment for some people with aggressive non-Hodgkin lymphoma that hasnt responded to other treatments. CAR T-cell therapy involves genetically modifying your own immune cells so that they attack your cancer. CAR T-cell therapy or other treatments actually may have a better chance at working than transplanting in this setting, Dr. Svoboda says.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Jakub Svoboda is a medical oncologist at Penn Medicine, andassociate professor of medicine at the Hospital of the University of Pennsylvania. Read More

Follow this link:
Could an Imaging Test Predict How Well Youll Respond to a Stem Cell Transplant? - SurvivorNet

Animal Stem Cell Therapy Market 2020 Size, Share, Trends Analysis Report by Application, Region (North America, South America, Asia, and Europe) and…

Research Organizations

To Understand How Covid-19 Impact Is Covered in This Report https://www.absolutereports.com/enquiry/request-covid19/13837427

The content of the study subjects, includes a total of 15 chapters:

Inquire or Share Your Questions If Any before the Purchasing This Report: https://www.absolutereports.com/enquiry/pre-order-enquiry/13837427

Table of Contents of Animal Stem Cell Therapy Market:

1 Market Overview

1.1 Animal Stem Cell Therapy Introduction

1.2 Market Analysis by Type

1.2.1 Type 1

1.2.2 Type 2

1.3 Market Analysis by Applications

1.3.1 Application 1

1.3.2 Application 2

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.4 South America, Middle East and Africa

1.4.4.5 Turkey Market States and Outlook (2014-2024)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Manufacture

2.1.1 Business Overview

2.1.2 Animal Stem Cell Therapy Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Manufacture Animal Stem Cell Therapy Sales, Price, Revenue, Gross Margin and Market Share (2019-2019)

3 Global Animal Stem Cell Therapy Sales, Revenue, Market Share and Competition by Manufacturer (2019-2019)

3.1 Global Animal Stem Cell Therapy Sales and Market Share by Manufacturer (2028-2019)

3.2 Global Animal Stem Cell Therapy Revenue and Market Share by Manufacturer (2018-2019)

3.3 Market Concentration Rate

3.3.1 Top 3 Animal Stem Cell Therapy Manufacturer Market Share in 2019

3.3.2 Top 6 Animal Stem Cell Therapy Manufacturer Market Share in 2019

3.4 Market Competition Trend

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source

Purchase this Report (Price 3480 USD for A Single-User License) at: https://www.absolutereports.com/purchase/13837427

Contact Us:

Name: Ajay More

Phone: US +1424 253 0807/ UK +44 203 239 8187

Email id- [emailprotected]

Our Other Reports:

Medical Face Mask Meltblown Nonwoven Fabric Market 2020 includes Size, Share, Impact of COVID-19, Trends and Forecast to 2026 Research Report by Absolute Reports

Blister Packaging Materials Market 2020 Size, Sale, Revenue, Regions, COVID-19 Impact, Price, Gross Margin, Growth, Status and Outlook to 2024 | Absolute Reports

Oral Polio Vaccines (OPV) Market 2020 by Manufactures, Comprehensive Analyze, Growth Strategies, Covid-19 Impact and Outlook to 2024 | Absolute Reports

Smart LED Indoor Signage Market 2020 Research Report by Size, Revenue, Opportunities, COVID-19 Impact, Status and Outlook to 2024 | Absolute Reports

Organic Flocculant Market 2020 includes Size, Share, Impact of COVID-19, Trends and Forecast to 2026 Research Report by Absolute Reports

Specialty Tape Market 2020 includes Size, Share, Impact of COVID-19, Trends and Forecast to 2026 Research Report by Absolute Reports

Global Hot Air Dryers Market 2020 Size, Status, Manufactures, Applications, Types, Impact of Covid-19 and Forecast to 2026 Research Report by Absolute Reports

Diamond Saw Wires Market 2020 by Size, Share, Growth Potential, Opportunities, Drivers, Covid-19 Impact and Forecast to 2024 | Absolute Reports

Motorcycle Wheel Weight Market 2020 with Strategies to Boost Growth, COVID-19 Impact, Manufactures, Types, Applications, Status and Outlook to 2024 | Absolute Reports

Global PUR Adhesive in Electronics Market 2020 Insights Report by Size, Status, Manufactures, Applications, Types and Forecast to 2026 | Absolute Reports

Global Low Tension Fuse Market 2020 Size, Status, Manufactures, Applications, Types, Impact of Covid-19 and Forecast to 2026 Research Report by Absolute Reports

Global Industrial Temperature Controllers Market 2020 Research Report with Covid-19 Impact, Industry Size, Revenue, Opportunities, Market Share and Growth Rate and Forecast to 2024 | Absolute Reports

Carbon Capture and Storage Market 2020 Research Report by Size, Revenue, Opportunities, COVID-19 Impact, Status and Outlook to 2024 | Absolute Reports

Global Mosquito Repellants Market 2020 by Key Players, Comprehensive Analyze, Growth Strategies, Covid-19 Impact and Forecast to 2024 | Absolute Reports

COVID-19 Impact on Global Diffractive Optical Elements Market 2020 with Strategies to Boost Growth, Manufactures, Types, Applications, Status and Outlook to 2024

See original here:
Animal Stem Cell Therapy Market 2020 Size, Share, Trends Analysis Report by Application, Region (North America, South America, Asia, and Europe) and...

Canine Stem Cell Therapy Market: Market Growth Factors, Applications, Regional Analysis, Key Players and Forecasts by 2026 – PRnews Leader

AllTheResearchs published a research report on the Canine Stem Cell Therapy market, which represents a study for the period from 2020 to 2026. The research provides a near look at the market scenario and dynamics impacting its growth. This report highlights the crucial developments along with other events happening in the market which are marking on the growth and opening doors for future growth in the coming years. Additionally, the report is built based on the macro- and micro-economic factors and historical data that can influence the growth.

The global Canine Stem Cell Therapy market was valued at US$ 118.5 Mn in 2018 and is expected to reach US$ 240.7 Mn in 2026, growing at a CAGR of 9.3% during the forecast period.

Request for Sample with Complete TOC and Figures & Graphs @ https://www.alltheresearch.com/sample-request/206

Key Players:

The global Canine Stem Cell Therapy market has been comprehensively analyzed and the different companies that occupy a large percentage of the market share in the regions mentioned have been listed out in the report. Industry trends that are popular and are causing a resurgence in the market growth are identified. A strategic profile of the companies is also carried out to identify the various subsidiaries that they own in the different regions and who are responsible for daily operations in these regions.

The Key Players Covered in Canine Stem Cell Therapy Market Study are:

How Report will help you to make decisions for business:

Before purchasing the report, lets discuss with the analyst @ https://www.alltheresearch.com/speak-to-analyst/206

Canine Stem Cell Therapy Market Segmentation

Canine Stem Cell Therapy market is split by Type and by Application. For the period 2015-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market Segmentation by Type:

Market Segmentation by Applications:

COVID-19 Impact on Canine Stem Cell Therapy Market:

The outbreak of COVID-19 has brought along a global recession, which has impacted several industries. Along with this impact COVID Pandemic has also generated few new business opportunities for Canine Stem Cell Therapy Market. Overall competitive landscape and market dynamics of Canine Stem Cell Therapy has been disrupted due to this pandemic. All these disruptions and impacts has been analysed quantifiably in this report, which is backed by market trends, events and revenue shift analysis. COVID impact analysis also covers strategic adjustments for Tier 1, 2 and 3 players of Canine Stem Cell Therapy Market.

Get Brief Information on Pre COVID-19 Analysis and Post COVID-19 Opportunities in Canine Stem Cell Therapy Market @ https://www.alltheresearch.com/impactC19-request/206

Research objectives:

Browse Full Research report along with TOC, Tables & Figures: https://www.alltheresearch.com/report/206/Canine Stem Cell Therapy

About AllTheResearch:

AllTheResearch was formed with the aim of making market research a significant tool for managing breakthroughs in the industry. As a leading market research provider, the firm empowers its global clients with business-critical research solutions. The outcome of our study of numerous companies that rely on market research and consulting data for their decision-making made us realise, that its not just sheer data-points, but the right analysis that creates a difference.While some clients were unhappy with the inconsistencies and inaccuracies of data, others expressed concerns over the experience in dealing with the research-firm. Also, same-data-for-all-business roles was making research redundant. We identified these gaps and built AllTheResearch to raise the standards of research support.

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:

Contact Name: Rohan S.

Email: [emailprotected]

Phone: +1 (407) 768-2028

Continued here:
Canine Stem Cell Therapy Market: Market Growth Factors, Applications, Regional Analysis, Key Players and Forecasts by 2026 - PRnews Leader

Next Steps: What to Do When the First Non-Hodgkin Lymphoma Treatment You Try Doesnt Work – SurvivorNet

Dr. Jennifer Crombie Dana-Farber Cancer Institute

About 60%of people with non-Hodgkin lymphoma, and specifically people with the most common subtype, diffuse large B-cell lymphoma, who go on the combination drug treatment R-CHOPwill be cured. Yet that still means about 40% of people will finish this treatment, only to discover that they still have to worry about their cancer.

Fortunately, the bounty of new treatments that have come out in recent years have given hope to people who didnt respond the first time around. Dr. Jennifer Crombie, medical oncologist at Dana-Farber Cancer Center, says she has good news for worried patients. If they fall into that subgroup of patients who dont have the response that were hoping for, or if their disease comes back after an initial remission, we do have other treatments, she tells SurvivorNet.

The typical next step if your cancer comes back or doesnt respond to R-CHOP is to get a different kind of chemotherapy than you had the first time. This is often called salvage chemotherapy. Each chemotherapy drug works a little bit differently for every person, and its possible that a new medicine will be more effective against your cancer.

Doctors follow up that second round of chemo with a stem cell transplant. These are patients own stem cells that we take from them and then give them back after additional chemotherapy, Dr. Crombie says.

Stem cells are the immature blood cells in your bone marrow. Some of them grow into the white blood cells that help your body fight infections. In non-Hodgkin lymphoma, those cells are abnormal. A transplant replaces the abnormal stem cells with healthy ones.

First, youll get high doses of chemotherapy to get rid of the damaged white blood cells. Then you get new, healthy stem cells either from yourself or a donor to repopulate your bone marrow. After a couple of weeks, the stem cells will start to make healthy new blood cells.

Because chemotherapy is part of the stem cell transplant, this treatment works best if your cancer is sensitive to chemotherapy. So you probably wont get a stem cell transplant unless your cancer is still sensitive to chemotherapy, Dr. Crombie says. But if you are responsive to chemotherapy, adding the stem cell transplant could put you into a lasting remission, or even cure your lymphoma.

What happens if a stem cell transplant doesnt keep your cancer at bay, or your cancer isnt sensitive to the salvage chemotherapy?

If the stem cell transplant doesnt put you into remission, your cancer comes back afterward, or your cancer doesnt respond to salvage chemotherapy, there is a new treatment that Dr. Crombie refers to as a breakthrough. Its called chimeric antigen receptor (CAR) T-cell therapy.

That is a novel therapy where a patients own immune cells, called T-cells, can be taken from the body and engineered in the lab, she says. Its sometimes referred to as a living therapy, because it uses actual living cells.

T-cells are the immune cells that help your body fight off germs. During this treatment, your doctor first separates out the T-cells from a sample of your blood. Those cells are then altered in a lab to make them produce special proteins chimeric antigen receptors on their surface. Then theyre multiplied, and millions of these cells go back into your body. Once there, the new fighter T-cells attach to a protein on the surface of cancer cells, and attack the cancer.

CAR T-cell therapy is also an exciting option for patients who havent been able to respond to chemotherapy before, or have had their disease come back despite prior therapy, Dr. Crombie says.

Now, researchers are investigating whether giving patients CAR-T cells earlier in treatment might keep their cancer away better than chemotherapy and stem cell transplant. The answer to that question is still unknown. Well have to await the data to see which is the better second choice in the future, Dr. Crombie tells SurvivorNet. Researchers are also studying the effectiveness of CAR-T cell therapy in other types of less aggressive non-Hodgkin lymphoma.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Jennifer Crombie is a medical oncologist at Dana-Farber Cancer Institute in Boston, Massachusetts. She is also aninstructor in medicine at Harvard Medical School. Read More

Dr. Jennifer Crombie Dana-Farber Cancer Institute

Fortunately, the bounty of new treatments that have come out in recent years have given hope to people who didnt respond the first time around. Dr. Jennifer Crombie, medical oncologist at Dana-Farber Cancer Center, says she has good news for worried patients. If they fall into that subgroup of patients who dont have the response that were hoping for, or if their disease comes back after an initial remission, we do have other treatments, she tells SurvivorNet.

Doctors follow up that second round of chemo with a stem cell transplant. These are patients own stem cells that we take from them and then give them back after additional chemotherapy, Dr. Crombie says.

Stem cells are the immature blood cells in your bone marrow. Some of them grow into the white blood cells that help your body fight infections. In non-Hodgkin lymphoma, those cells are abnormal. A transplant replaces the abnormal stem cells with healthy ones.

First, youll get high doses of chemotherapy to get rid of the damaged white blood cells. Then you get new, healthy stem cells either from yourself or a donor to repopulate your bone marrow. After a couple of weeks, the stem cells will start to make healthy new blood cells.

Because chemotherapy is part of the stem cell transplant, this treatment works best if your cancer is sensitive to chemotherapy. So you probably wont get a stem cell transplant unless your cancer is still sensitive to chemotherapy, Dr. Crombie says. But if you are responsive to chemotherapy, adding the stem cell transplant could put you into a lasting remission, or even cure your lymphoma.

What happens if a stem cell transplant doesnt keep your cancer at bay, or your cancer isnt sensitive to the salvage chemotherapy?

If the stem cell transplant doesnt put you into remission, your cancer comes back afterward, or your cancer doesnt respond to salvage chemotherapy, there is a new treatment that Dr. Crombie refers to as a breakthrough. Its called chimeric antigen receptor (CAR) T-cell therapy.

That is a novel therapy where a patients own immune cells, called T-cells, can be taken from the body and engineered in the lab, she says. Its sometimes referred to as a living therapy, because it uses actual living cells.

T-cells are the immune cells that help your body fight off germs. During this treatment, your doctor first separates out the T-cells from a sample of your blood. Those cells are then altered in a lab to make them produce special proteins chimeric antigen receptors on their surface. Then theyre multiplied, and millions of these cells go back into your body. Once there, the new fighter T-cells attach to a protein on the surface of cancer cells, and attack the cancer.

CAR T-cell therapy is also an exciting option for patients who havent been able to respond to chemotherapy before, or have had their disease come back despite prior therapy, Dr. Crombie says.

Now, researchers are investigating whether giving patients CAR-T cells earlier in treatment might keep their cancer away better than chemotherapy and stem cell transplant. The answer to that question is still unknown. Well have to await the data to see which is the better second choice in the future, Dr. Crombie tells SurvivorNet. Researchers are also studying the effectiveness of CAR-T cell therapy in other types of less aggressive non-Hodgkin lymphoma.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Jennifer Crombie is a medical oncologist at Dana-Farber Cancer Institute in Boston, Massachusetts. She is also aninstructor in medicine at Harvard Medical School. Read More

See more here:
Next Steps: What to Do When the First Non-Hodgkin Lymphoma Treatment You Try Doesnt Work - SurvivorNet

Philadelphia Based Company Wants to Bring Back the Dead With Stem Cells – Gilmore Health News

Waking up the dead science fiction or a Halloween night horror movie? No, thats the goal of Bioquarks ReAnima project. The project aims to restore neuronal activity in brain dead people by combining several techniques: stem cell injection, nerve stimulation, and laser.

Stem Cells

Stem cells are increasingly becoming a serious treatment option for many nervous disorders: Alzheimers, Parkinsons, brain injuries, etc. So why not repair the brains of the dead to bring them back to life? This idea, worthy of a science fiction (or horror) film, is the crazy project of a company based in Philadelphia: Bioquark.

Read Also: Old Human Cells Successfully Rejuvenated Via Stem Cell Technology

This is not the first time that the company wants to participate in such an experiment. In 2016, the ReAnima study was launched in Bangalore, India, together with Himanshu Bansal, an orthopedic surgeon at Anupam Hospital. His plan was to combine several techniques to revive 20 brain dead people.

ReAnima consisted of injecting patients with mesenchymal stem cells and peptides that help regenerate brain cells; these peptides were to be supplied by Bioquark. In addition to these injections, transcranial laser stimulation and nerve stimulation were planned. This project was stopped by the Indian authorities in November last year, as revealed then by Science magazine.

But the company did not admit defeat. This time, according to the company, they are close to finding a new location for their clinical trials. Ira Pastor, CEO of Bioquark, told the Stat website that the company would announce the process in Latin America in the coming months.

Read Also: HGH Improves Memory In Stroke Victims Study Shows

If the experiment follows the same protocol as planned in India, it may involve 20 people. The clinical trial would again involve the injection of the patients stem cells, fat, blood Then a mixture of peptides would be injected into the spinal cord to stimulate the growth of new nerve cells. This compound, called BQ-A, was tested on animal models with head trauma. In addition, the nerves would be stimulated by nerve stimulation and 15 days of laser therapy to stimulate the neurons to make nerve connections. Researchers could then monitor the effects of this treatment using electroencephalograms.

But such a protocol raises many questions: How would a clinical trial be conducted on officially deceased people? If the person recovers some brain activity, in what state would he be? Will families be given false hope with a treatment that may take a long time?

Read Also: UC San Diego: Adult Brain Cells Revert to Younger State Following Injury, Study Shows

There is no indication that such a protocol will work. The company has not even tested the entire treatment on animal models! The mentioned treatments, such as injection of stem cells or transcranial stimulation, were tested in other situations, but not in cases of brain death. In an article published in 2016, neurologist Ariane Lewis and bioethicist Arthur Caplan stressed that the experiment had no scientific basis and that it gave families false and cruel hopes of a cure.

Experiment to raise the dead blocked in India

Response to a trial on reversal of Death by Neurologic Criteria

Links You May Like:

Is NAD+ The Anti Aging Substance Mankind Has Been Searching For?

Anti-Aging: HGH Can Reduce Biological Age by One Year and a Half Study Shows

Growth Factor Plus Review: Benefits, Ingredients, Side effects, Cost and Testimonials

HGH and Its Anti Aging Effects On The Skin

See the original post here:
Philadelphia Based Company Wants to Bring Back the Dead With Stem Cells - Gilmore Health News

What Are the Treatment Options When Lymphoma Returns? – SurvivorNet

Dr. Stephen Schuster Penn Medicine

Finally entering into remission after youve gone through several weeks or months worth of treatment for non-Hodgkin lymphoma can feel like a huge victory. Sometimes remissions are long lasting, but in a certain percentage of people, the cancer can eventually return. If your cancer does stage a comeback, your doctor will be ready with another round of treatment that oncologists call second-line therapy.

What tools do we have for the second line? Well, the standard right now is the high-dose chemotherapy with autologous stem cell rescue approach, Dr. Stephen Schuster, medical oncologist at Penn Medicine, tells SurvivorNet. An autologous stem cell transplant gives you an infusion of your own stem cells the preliminary cells that will eventually grow into new blood cells to replace the ones chemotherapy destroys. It allows your doctor to give you very high doses of chemo to treat your cancer.

In the late 1980s and 1990s, stem cell therapy worked pretty well in about one-third of people who received it. But as doctors improved upon the first-line treatment in the early 2000s by combining chemotherapy with the monoclonal antibody rituximab (Rituxan) into a drug cocktail called R-CHOP, stem cell therapy no longer worked as well in the second line. The hunt was on for a new way to treat relapsed non-Hodgkin lymphoma.

Fortunately, several new and improved cancer treatments have been introduced, and other novel therapies are under investigation. It took us from the 1970s to the late 90s to improve on the four drug combination CHOP, which is still the standard, adding rituximab to that, Dr. Schuster says. Today, not only have the treatments gotten better, but the pace of new drug development has sped up, he says. Several new immunotherapies have come out, just in the last few years.

One new therapeutic option if your cancer has returned is immunotherapy harnessing the power of your immune system to go after your cancer. [Immunotherapy is] frequently discussed in the popular scientific literature, Dr. Schuster says. Some of it sounds like science fiction. Its very cool stuff.

One group of immunotherapy drugs, collectively known as the monoclonal antibodies, use a protein called an antibody to home in on a target on the surface of cancer cells. Rituxan is one such drug.

A few new immunotherapy drugs have been approved for non-Hodgkin lymphoma in recent years:

Chimeric antigen receptor (CAR) T-cell therapy is one of the newest high-tech cancer treatments. During this therapy, your treatment team will take your own immune cells, called T cells, and genetically modify and multiply them in a lab so that they attach to proteins on the surface of your lymphoma cells and attack them.

These treatments each work in a slightly different way. And they can be effective for people whove tried and failed at two previous treatments.

Were coming up with the best approaches for people who were not successfully treated by first- or second-line approaches, Dr. Schuster says.There are currently two FDA-approved CAR T products for people with diffuse large B-cell lymphoma who have failed two prior lines of treatment.

Say youve tried three separate treatments and your cancer has come back again. It can be frustrating to face yet another round of treatment, but here again, innovation is your friend.

Soon, another therapy called bispecific antibodies or bispecific T-cell engagers (BiTEs),is likely to be added to the mix, says Dr. Schuster. Unlike monoclonal antibodies, which attach to only one target, bispecific antibodies bind to two targets at once. They essentially pull together your immune cells and cancer cells to help your immune system more effectively treat your cancer.

With so many non-Hodgkin lymphoma therapies available, theres a much better chance that your doctor will eventually find something that works for your cancer. If youve been through several rounds of treatment without success, you can always consider enrolling in a clinical trial of a new and as-yet unapproved drug that be more effective than anything youve already tried.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Stephen Schuster is a medical oncologist and director of the Lymphoma Program at Penn Medicine. He is also theRobert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clinical Care and Research. Read More

Dr. Stephen Schuster Penn Medicine

What tools do we have for the second line? Well, the standard right now is the high-dose chemotherapy with autologous stem cell rescue approach, Dr. Stephen Schuster, medical oncologist at Penn Medicine, tells SurvivorNet. An autologous stem cell transplant gives you an infusion of your own stem cells the preliminary cells that will eventually grow into new blood cells to replace the ones chemotherapy destroys. It allows your doctor to give you very high doses of chemo to treat your cancer.

Fortunately, several new and improved cancer treatments have been introduced, and other novel therapies are under investigation. It took us from the 1970s to the late 90s to improve on the four drug combination CHOP, which is still the standard, adding rituximab to that, Dr. Schuster says. Today, not only have the treatments gotten better, but the pace of new drug development has sped up, he says. Several new immunotherapies have come out, just in the last few years.

One new therapeutic option if your cancer has returned is immunotherapy harnessing the power of your immune system to go after your cancer. [Immunotherapy is] frequently discussed in the popular scientific literature, Dr. Schuster says. Some of it sounds like science fiction. Its very cool stuff.

One group of immunotherapy drugs, collectively known as the monoclonal antibodies, use a protein called an antibody to home in on a target on the surface of cancer cells. Rituxan is one such drug.

A few new immunotherapy drugs have been approved for non-Hodgkin lymphoma in recent years:

Chimeric antigen receptor (CAR) T-cell therapy is one of the newest high-tech cancer treatments. During this therapy, your treatment team will take your own immune cells, called T cells, and genetically modify and multiply them in a lab so that they attach to proteins on the surface of your lymphoma cells and attack them.

These treatments each work in a slightly different way. And they can be effective for people whove tried and failed at two previous treatments.

Were coming up with the best approaches for people who were not successfully treated by first- or second-line approaches, Dr. Schuster says.There are currently two FDA-approved CAR T products for people with diffuse large B-cell lymphoma who have failed two prior lines of treatment.

Say youve tried three separate treatments and your cancer has come back again. It can be frustrating to face yet another round of treatment, but here again, innovation is your friend.

Soon, another therapy called bispecific antibodies or bispecific T-cell engagers (BiTEs),is likely to be added to the mix, says Dr. Schuster. Unlike monoclonal antibodies, which attach to only one target, bispecific antibodies bind to two targets at once. They essentially pull together your immune cells and cancer cells to help your immune system more effectively treat your cancer.

With so many non-Hodgkin lymphoma therapies available, theres a much better chance that your doctor will eventually find something that works for your cancer. If youve been through several rounds of treatment without success, you can always consider enrolling in a clinical trial of a new and as-yet unapproved drug that be more effective than anything youve already tried.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Stephen Schuster is a medical oncologist and director of the Lymphoma Program at Penn Medicine. He is also theRobert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clinical Care and Research. Read More

Excerpt from:
What Are the Treatment Options When Lymphoma Returns? - SurvivorNet

Stem Cell Therapy Market | Growth Strategies Adopted By Top Key Players,Future Trends ,Application Worldwide And Assessment To 2026 – PRnews Leader

Complete study of the global Stem Cell Therapy market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Stem Cell Therapy industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Stem Cell Therapy production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

The global Stem Cell Therapy market report reveals pertinent data on segment performance, growth potential in the coming years as well as vendor and manufacturer activities, aligning appropriately with consumption and production developments.

Get Exclusive Sample of Report on Stem Cell Therapy market is available @ https://www.adroitmarketresearch.com/contacts/request-sample/691

The pandemic of Coronavirus (COVID-19) has affected every aspect of life worldwide. This has brought along several changes in market conditions. The rapidly changing industry scenario and initial and future assessment of the impact are covered in the report. The Stem Cell Therapy market report puts together a concise analysis of the growth factors influencing the current business scenario across various regions. Significant information pertaining to the industry analysis size, share, application, and statistics are summed in the report in order to present an ensemble prediction.

Some of the key reader queries that have been adequately addressed in the report include, top vendors and their growth triggering business strategies, regional outlook and growth hotspot identification, followed by prominent growth retardants, challenges and threat probability which result in dwarfed growth outlook. Further, to instill new market participation amongst novel enthusiast, this report clearly focuses teeming business opportunities that ensure smooth rise despite odds and growing competition.

Browse the complete report Along with TOC @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Stem Cell Therapy industry. In order to fulfill the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Stem Cell Therapy Market Segmentation

Type Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCs Bone Marrow-Derived Mesenchymal SCs Embryonic SCs Other Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal Disorders Wounds & Injuries Cardiovascular Diseases Gastrointestinal Diseases Immune System Diseases Other Applications

Key questions answered in the report:

1. What is the growth potential of the Stem Cell Therapy market? 2. Which product segment will grab a lions share? 3. Which regional market will emerge as a frontrunner in coming years? 4. Which application segment will grow at a robust rate? 5. What are the growth opportunities that may emerge in Stem Cell Therapy industry in the years to come? 6. What are the key challenges that the global Stem Cell Therapy market may face in future? 7. Which are the leading companies in the global Stem Cell Therapy market? 8. Which are the key trends positively impacting the market growth? 9. Which are the growth strategies considered by the players to sustain hold in the global Stem Cell Therapy market?

If you have any questions on this report, please reach out to us @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691

About Us :

Contact Us :

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX75204, U.S.A. Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Read more:
Stem Cell Therapy Market | Growth Strategies Adopted By Top Key Players,Future Trends ,Application Worldwide And Assessment To 2026 - PRnews Leader

Here’s What Happens When Lab-Grown Mini-Lungs Are Exposed to SARS-CoV-2 – ScienceAlert

Scientists working on a lab-grown mini-lung are now using their living model to better understand the current pandemic and potential new treatments.

The most recent version of this unique organoid is based entirely on human stem cells, known to repair the deepest parts of our lungs. When the researchers exposed it to SARS-CoV-2, the results were illuminating.

Dropping just one of these self-renewing units into a dish containing a tailored growth solution can produce millions of cells in a clump that resembles the tiny air sacs in human lungs.

Known as alveoli, these balloon-like sacs have shown diffuse damage in fatal cases of COVID-19, and while this havoc is often attributed to a storm of immune cells called cytokines, we're still figuring out how lung injury actually comes about.

The new mini-model gives us a glimpse of the battle on a molecular scale, and while it's nowhere near as complex as a real human lung, that's also what makes it easier to control and observe.

The unique organoid includes just one type of lung stem cell, known as an alveolar type 2 epithelial cell (AT2), which has the ability to self-renew, differentiate into other lung cells, keep the sac open with surfactants, and directly bind to viruses.

When the SARS-CoV-2 virus was introduced into this organoid's dish, researchers say the virus quickly infected the AT2 cells and spread throughout the alveoli-like structure.

The infection also triggered an inflammatory response in the organoid, reducing the production and proliferation of surfactant and inducing cell death, sometimes in surrounding areas that hadn't even yet been touched by the virus.

"This is a major breakthrough for the field because we were using cells that didn't have purified cultures," explains Ralph Baric, an epidemiologist, microbiologist, and immunologist at the University of North Carolina.

"This is incredibly elegant work to figure out how to purify and grow AT2 cells in culture."

Analysing the gene expression of these mini-organs, researchers found the inflammatory state triggered by the SARS-CoV-2 infection led to the production of interferons, cytokines, chemokines, and activation of genes related to cell death.

What's more, these signatures showed "striking similarity" to what's seen in severe COVID-19 patients.The results also match recent growing evidence that suggests severe cases of COVID-19 trigger a cytokine storm that may leave the lungs susceptible to damage.

Most of these observations, however, come from autopsies and have not been observed in living tissue.

This newly-developed model is a unique and versatile new way to study respiratory viruses in action, and it shows how a cascade of defences within stem cells themselves may cause more damage than good.

"It was thought cytokine storm happened due to the large influx of immune cells, but we can see it also happens in the lung stem cells themselves," says cell biologist Purushothama Rao Tata from Duke University.

"Now we have a way to figure out how to energise the cells to fight against this deadly virus," he adds.

In another set of experiments on the mini-lung, researchers found that administering low doses of interferons before infection slowed the spread of the virus, whereas reducing interferons before infection worsened the damage.

This suggests interferons are somehow mediating the immune response in our alveoli, slowing the cascade of cell death as the lung tries to get ahead of the infection.

But this may not be the whole picture; it's just a small insight into what's going on.Other recent studies show that while interferons might be a helpful treatment at certain stages of infection, at other times they can make matters worse.

While there are still many kinks and details that need to be ironed out in their model, researchers hope they can one day grow mini-lungs on which hundreds of experiments can be run at the same time, allowing us to figure out how the lung responds to infection and also how we can best protect it.

There's never been a more important time to learn more.

The study was published in Cell Stem Cell.

The rest is here:
Here's What Happens When Lab-Grown Mini-Lungs Are Exposed to SARS-CoV-2 - ScienceAlert

Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant…

This article was originally published here

Br J Haematol. 2020 Oct 29. doi: 10.1111/bjh.17131. Online ahead of print.

ABSTRACT

Although new multiple myeloma (MM) therapies are effective in alleviating some disease-associated symptoms (e.g. bone pain, fatigue, functional decline), they can result in additional toxicities, further impacting health-related quality of life (HRQoL). Here, we compared HRQoL and safety of lenalidomide-bortezomib-dexamethasone [RVd (n = 445)], bortezomib-melphalan-prednisone [VMP (n = 77)] and Vd or VMP (n = 588) in patients with newly diagnosed MM (NDMM) from the Connect MM Registry, a large, USA, multicentre, prospective observational cohort study. Functional Assessment of Cancer Therapy-Multiple Myeloma subscale, EuroQol-5D overall score and Bone Pain Inventory HRQoL scores were significantly improved with RVd versus Vd/VMP. Serious adverse event rates were similar in all groups. Treatment with RVd maintained HRQoL in this real-world, largely community-based population of patients with NDMM.

PMID:33118614 | DOI:10.1111/bjh.17131

Link:
Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant...